DMCC Q1 FY27: consolidated revenue nearly doubles YoY, PAT surges 163% to ₹20.4 Cr
PAT +163.04% YoY · revenue +99.16% · margins expanding
₹253.01 Cr
+99.16% YoY
₹20.4 Cr
+163.04% YoY
8.05%
+2pp YoY
₹8.18
DMCC Speciality Chemicals reported a strong Q1 FY27 (quarter ended June 30, 2026): consolidated revenue nearly doubled to ₹253.01 Cr, up 99.2% YoY from ₹127.04 Cr and 42.4% QoQ from ₹177.64 Cr. Consolidated PAT surged 163.0% YoY to ₹20.40 Cr (from ₹7.76 Cr) and 166.5% QoQ (from ₹7.65 Cr), with EPS at ₹8.18 versus ₹3.11 a year ago and ₹3.07 last quarter. Standalone figures (revenue ₹252.99 Cr, PAT ₹20.41 Cr) are effectively identical to consolidated — the sole subsidiary, DMCC (Europe) GmbH, added just ₹1.64 lakh of revenue this quarter, so the two bases tell the same story.
Q1 FY-2027 vs prior quarters
Net profit margin expanded to 8.05% of total income, from 6.09% a year ago and 4.30% last quarter. EBITDA-level operating margin came in at 13.59%, up sharply from 9.96% QoQ but only marginally above the 13.28% posted a year ago. The margin gain is a volume story, not cost relief: raw-material consumption rose to roughly 78% of total income this quarter versus about 61% a year ago, consistent with the raw-material price pressure management flagged on the FY26 Q4 call. Total expenses grew 94.2% YoY to ₹226.08 Cr, just below revenue's 99.2% growth — enough operating leverage to lift margins modestly, but the cost structure is visibly heavier than a year ago. No exceptional items appear in either period, so the growth is entirely operating.
The stock went into the print at ₹316, up 19.2% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
Management indicated that while the current situation remains volatile, they expect FY27 to be better than FY25-26 for the specialty chemical segment, though precise projections are difficult. They are seeing some initial commercial sales in new specialty products, particularly in boron derivatives, and expect to incre
— This quarter: beat
On the FY26 Q4 call, management guided that FY27 would be better than FY25-26 for the specialty chemicals segment while flagging near-term volatility, raw-material and working-capital pressure, and early boron-derivative commercial traction; a subsequent earnings-call summary also noted a bearish boron market tied to an energy-driven supply glut expected to weigh on demand into Q1 FY27. Against that cautious framing, a near-doubling of revenue and 163% YoY profit growth reads as a clear beat of the qualitative guidance, even as the flagged raw-material cost pressure shows up in the expense mix. No brokerage consensus or published Q1 FY27 preview for DMCC could be found, so there is no street number to benchmark against, and no separate management press release accompanied this filing. The only other disclosed development this quarter is a minor ₹1.06 Cr ITC demand appeal from May, immaterial to the P&L. Results are unaudited, with the statutory auditor issuing an unmodified limited-review opinion on both statements.
W1
Whether raw-material cost intensity (~78% of revenue in Q1 FY27 vs ~61% YoY) eases in Q2 FY27, as management said it expects to manage the pressure
W2
Boron-derivative specialty-product ramp and rising R&D intensity flagged in the FY26 Q4 call — watch for commercial traction/mix disclosure
W3
Progress toward management's stated goal of specialty chemicals reaching at least 50% of total revenue